Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $1.67 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 430.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,950 shares of the pharmaceutical company’s stock after acquiring an additional 3,206 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Vertex Pharmaceuticals were worth $1,669,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of VRTX. Brighton Jones LLC raised its holdings in shares of Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Vertex Pharmaceuticals by 25.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,827 shares of the pharmaceutical company’s stock valued at $886,000 after purchasing an additional 374 shares during the last quarter. Modern Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at about $458,000. TrueWealth Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 12.4% during the 2nd quarter. TrueWealth Advisors LLC now owns 1,223 shares of the pharmaceutical company’s stock worth $544,000 after buying an additional 135 shares during the last quarter. Finally, Centurion Wealth Management LLC acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $223,000. Institutional investors own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 63,781 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the transaction, the chairman directly owned 24,026 shares of the company’s stock, valued at $10,792,479.20. This trade represents a 72.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $474.99, for a total value of $2,137,455.00. Following the sale, the executive vice president directly owned 42,293 shares of the company’s stock, valued at $20,088,752.07. This represents a 9.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 165,105 shares of company stock worth $73,858,523 in the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ VRTX opened at $463.86 on Monday. The company has a market capitalization of $117.69 billion, a PE ratio of 32.71 and a beta of 0.31. The stock’s 50 day moving average price is $443.50 and its 200-day moving average price is $427.04. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the company earned $4.38 earnings per share. The company’s quarterly revenue was up 11.0% on a year-over-year basis. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported progress advancing suzetrigine into a Phase‑3 trial for diabetic nerve pain — a meaningful new indication that could broaden revenue beyond its cystic fibrosis franchise. Vertex Advances Suzetrigine Phase 3 Trial
• Positive Sentiment: Wolfe Research upgraded the stock recently, and several sell‑side firms have raised price targets (e.g., Leerink, Wells Fargo), supporting upside expectations and a consensus target near ~$504. Vertex Stock Rating Upgraded by Wolfe Research
• Neutral Sentiment: Market recaps note short‑term price weakness even as fundamentals and analyst coverage remain constructive — context for volatile daily moves but not necessarily a change to the longer‑term thesis. Vertex Stock Dips While Market Gains: Key Facts
• Neutral Sentiment: Another market note highlighted the recent down‑day versus a broader market uptick — useful color for traders but not new company‑specific catalysts. Vertex Stock Falls Amid Market Uptick
• Negative Sentiment: Two senior executives disclosed sizable open‑market sales this week — EVP Charles Wagner Jr. sold 9,532 shares (~$4.4M at ~$461/share) and EVP Ourania Tatsis sold 4,500 shares (~$2.14M at ~$475/share). Large insider sales can pressure sentiment even if not tied to company fundamentals. Charles Wagner, Jr. Sells 9,532 Shares
• Negative Sentiment: Separate filing shows EVP Ourania Tatsis’ 4,500‑share sale and a near‑10% reduction in her position — another factor likely weighing on intraday selling pressure. Ourania Tatsis Insider Sale
• Negative Sentiment: A Seeking Alpha piece and some sell‑side notes discuss the near‑term cost and execution risk of expanding beyond cystic fibrosis, which can temper investor appetite until new indications (like suzetrigine) de‑risk. The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)

Analysts Set New Price Targets

VRTX has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada reduced their price objective on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 4th. Barclays boosted their target price on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. Morgan Stanley set a $564.00 price objective on Vertex Pharmaceuticals in a research note on Friday, December 5th. Finally, JPMorgan Chase & Co. increased their price target on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $503.80.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.